Trial Profile
A phase IIa trial of Doranidazole for non-small cell lung cancer (NSCLC).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Aug 2017
Price :
$35
*
At a glance
- Drugs Doranidazole (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 21 Aug 2017 New trial record